Cerus Corp (NASDAQ:CERS) Institutional Investors Sentiment Index Improved in 2017 Q4

April 17, 2018 - By Peter Erickson

Sentiment for Cerus Corp (NASDAQ:CERS)

Cerus Corp (NASDAQ:CERS) institutional sentiment increased to 1.45 in Q4 2017. Its up 0.13, from 1.32 in 2017Q3. The ratio improved, as 45 institutional investors started new and increased holdings, while 31 trimmed and sold stakes in Cerus Corp. The institutional investors in our partner’s database now own: 58.96 million shares, up from 57.26 million shares in 2017Q3. Also, the number of institutional investors holding Cerus Corp in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 25 Increased: 31 New Position: 14.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $706.30 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

The stock increased 1.87% or $0.1 during the last trading session, reaching $5.45. About 524,079 shares traded. Cerus Corporation (NASDAQ:CERS) has risen 26.07% since April 17, 2017 and is uptrending. It has outperformed by 14.52% the S&P500.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on May, 2. They expect $-0.12 EPS, up 33.33 % or $0.06 from last year’s $-0.18 per share. After $-0.10 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Lesa Sroufe & Co holds 1.51% of its portfolio in Cerus Corporation for 540,752 shares. Elk Creek Partners Llc owns 6.55 million shares or 1.3% of their US portfolio. Moreover, Millrace Asset Group Inc. has 1.28% invested in the company for 395,202 shares. The New York-based Salzhauer Michael has invested 0.54% in the stock. First Midwest Bank Trust Division, a Illinois-based fund reported 784,416 shares.#img1#

Since January 1, 0001, it had 1 buy, and 5 selling transactions for $597,723 activity.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Ratings analysis reveals 100% of Cerus Corp’s analysts are positive. Out of 2 Wall Street analysts rating Cerus Corp, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $4.0 while the high is $6.0. The stock’s average target of $6 is 10.09% above today’s ($5.45) share price. CERS was included in 5 notes of analysts from October 30, 2017. Robert W. Baird maintained the stock with “Buy” rating in Wednesday, January 24 report. Robert W. Baird maintained it with “Buy” rating and $5.0 target in Thursday, November 30 report. Cantor Fitzgerald maintained it with “Buy” rating and $6.0 target in Thursday, March 8 report. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Monday, January 8 by Cantor Fitzgerald. The rating was maintained by Robert W. Baird with “Buy” on Monday, October 30.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.